ArticleBlood2020
How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation.
Article in Blood, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07709013 (Use of Leflunomide as Primary Prophylaxis Against Cytomegalovirus), which is not on this map. Cited by 87 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Use of Leflunomide as Primary Prophylaxis Against Cytomegalovirus (CMV) Reactivation in Haploidentical Haematopoietic Stem Cell Transplant (HIT) - Single, Arm, Phase 2 Clinical Trial
Who cites it
87 citing papers in PubMed, 2 syntheses or guidelines pooled it, 161 citations in OpenAlex.
- Antiviral Agents for Preventing Cytomegalovirus Disease in Recipients of Hematopoietic Cell Transplantation.Viruses · 2024Pooled it
- A Systematic Review of the Clinical Pharmacokinetics, Pharmacodynamics and Toxicodynamics of Ganciclovir/Valganciclovir in Allogeneic Haematopoietic Stem Cell Transplant Patients.Clinical pharmacokinetics · 2021Pooled it
- [Phase Ⅲ, multicenter, randomized, double-blinded, positive-controlled trial on the efficacy and safety of maribavir compared with valganciclovir in the treatment of post-transplant cytomegalovirus infection: Subgroup analysis of AURORA Trial in the Chinese population].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Trial
- Treatment for First Cytomegalovirus Infection Post-Hematopoietic Cell Transplant in the AURORA Trial: A Multicenter, Double-Blind, Randomized, Phase 3 Trial Comparing Maribavir With Valganciclovir.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Trial
- Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis.Blood · 2021Trial
- Early Secondary Graft Failure After Complete Donor Chimerism with Autologous Recovery Following Haploidentical HSCT for Relapsed B-ALL.Blood cell therapy · 2026Article
- Threshold for cytomegalovirus DNA PCR for preemptive treatment after allogeneic stem cell transplantation.International journal of hematology · 2026Article
- Human cytomegalovirus control in allogeneic stem cell transplant recipients in the letermovir era - emerging humoral and cellular players.Haematologica · 2026Article
- Adaptable, quantitative CRISPR/Cas12a-based assay for cytomegalovirus DNA in infant saliva.Scientific reports · 2026Article
- Comparison of quantitative PCR values and antigenemia for CMV monitoring in hematopoietic cell transplant recipients.International journal of hematology · 2026Article
- Time-series clustering analysis reveals distinct patterns of cytomegalovirus viremia in critically ill adults.Intensive care medicine experimental · 2026Article
- Assessing the significance of cytomegalovirus reactivation in recipients of allogeneic hematopoietic stem cell transplantation: a cohort study.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas · 2026Observational
- Changing scenario in prevention and management of CMV infections in pediatric hematopoietic stem cell transplant patients.Bone marrow transplantation · 2026Review
- Risk stratification for CMV reactivation in sepsis patients: development of an interpretable machine learning model.BMC infectious diseases · 2025Article
- Article
- Cytomegalovirus reactivation in patients with large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy.International journal of hematology · 2025Article
- The Immunoregulatory Mechanisms of Human Cytomegalovirus from Primary Infection to Reactivation.Pathogens (Basel, Switzerland) · 2025Review
- Chimeric Antigen Receptor Immunotherapy for Infectious Diseases: Current Advances and Future Perspectives.Pathogens (Basel, Switzerland) · 2025Review
- Antiviral potential of Vδ2 T cells in children given TCR αβ/CD19 cell-depleted HLA-haploidentical HSCT.Blood advances · 2025Article
- How Should Cytomegalovirus Infection Be Managed in Allogeneic Hematopoietic Stem Cell Transplant Recipients? A Clinical Grand Round.Infection & chemotherapy · 2025Review
27 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
Abstract
Cytomegalovirus (CMV) reactivation remains one of the most common and life-threatening infectious complications following allogeneic hematopoietic stem cell transplantation, despite novel diagnostic technologies, several novel prophylactic agents, and further improvements in preemptive therapy and treatment of established CMV disease. Treatment decisions for CMV reactivation are becoming increasingly difficult and must take into account whether the patient has received antiviral prophylaxis, the patient's individual risk profile for CMV disease, CMV-specific T-cell reconstitution, CMV viral load, and the potential drug resistance detected at the time of initiation of antiviral therapy. Thus, we increasingly use personalized treatment strategies for the recipient of an allograft with CMV reactivation based on prior use of anti-CMV prophylaxis, viral load, the assessment of CMV-specific T-cell immunity, and the molecular assessment of resistance to antiviral drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.